Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Ayahuasca healing and science / / edited by Beatriz Caiuby Labate and Clancy Cavnar
| Ayahuasca healing and science / / edited by Beatriz Caiuby Labate and Clancy Cavnar |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (267 pages) |
| Disciplina | 615.7883 |
| Soggetto topico |
Ayahuasca - Physiological effect
Ayahuasca - Therapeutic use Ús terapèutic Efectes fisiològics |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-55688-3 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910483772603321 |
| Cham, Switzerland : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Baccharis : from evolutionary and ecological aspects to social uses and medicinal applications / / edited by Geraldo Wilson Fernandes, Yumi Oki, and Milton Barbosa
| Baccharis : from evolutionary and ecological aspects to social uses and medicinal applications / / edited by Geraldo Wilson Fernandes, Yumi Oki, and Milton Barbosa |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2022] |
| Descrizione fisica | 1 online resource (580 pages) |
| Disciplina | 583.983 |
| Soggetto topico |
Baccharis
Pharmacology Ús terapèutic |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-83511-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910548166203321 |
| Cham, Switzerland : , : Springer, , [2022] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Botulinum toxin treatment of pain disorders / / Bahman Jabbari
| Botulinum toxin treatment of pain disorders / / Bahman Jabbari |
| Autore | Jabbari Bahman |
| Edizione | [2nd ed.] |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2022] |
| Descrizione fisica | 1 online resource (438 pages) |
| Disciplina | 297.05 |
| Soggetto topico |
Botulinum toxin - Therapeutic use
Toxina botulínica Ús terapèutic |
| Soggetto genere / forma | Llibres electrònics |
| ISBN |
9783030996505
9783030996499 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Preface -- Contents -- Chapter 1: The History of Botulinum Neurotoxin Development -- Introduction -- Biology and Basic Science -- Neurologists: Clinical Neurotoxicologists in the United States -- PREEMPT Group (Drs. Silberstien, Dodick, Aurora, Lipton, Blumenfeld, and Others) -- Germany -- Austria -- References -- Chapter 2: Molecular Structure, Mode of Action, Immunology, Safety, and Side Effects of BoNTs -- Introduction -- Structure of Botulinum Neurotoxin and Its Mode of Action -- Diffusion and Spread of Neurotoxins -- Immunology of BoNTs -- Side Effects of BoNTs -- References -- Chapter 3: Analgesic Effects of Botulinum Neurotoxins: Data from Animal Studies Volunteers -- Introduction -- Pathophysiology of Pain at Peripheral and Central Levels -- Pain Modulation -- Data from Animal Studies -- Effect of Botulinum Toxins on Pain Channels and Receptors -- Effect on Sodium Channels -- Effect on Transient Receptor Potentials (TRP) Channels -- Effect on Purinergic Channels -- The Role of Nerve Growth Factor (NGF) in Pain -- The Effects of Botulinum Toxins on Inflammation -- Spinal Cord Gabaergic Neurons and Pain: Effects of Botulinum Toxins -- Effects of Botulinum Toxins on Opioid Channels -- Opioid Receptors -- BoNT Effects on Nerve Regeneration and Nerve Recovery -- Evidence for Central Analgesic Effect of Botulinum Neurotoxins -- Additional Mechanisms Potentially Promoting the Analgesic Effects of BoNTs in Pain -- Conclusion -- References -- Chapter 4: Botulinum Toxin Therapy for Neuropathic Pain (NP) -- Neuropathic Pain: Definition and Pathophysiology -- Postherpetic Neuralgia (PHN) -- Treatment -- BoNT Studies in Postherpetic Neuralgia (PHN) -- Case Report -- Comment -- The Effect of Botulinum Toxin on Itch Associated with PHN -- Posttraumatic Neuralgia -- Treatment -- BoNT Treatment of Posttraumatic Neuralgia -- Case Report.
Metabolic and Drug-Induced Painful Peripheral Neuropathies -- Diabetic Neuropathy -- Pathophysiology -- Treatment of Painful Diabetic Neuropathy (PDN) -- BoNT Treatment in Diabetic Neuropathy -- Comment -- Painful Neuropathy Related to Drugs and Chemotherapeutic Agents -- Case Report -- Comment -- Complex Regional Pain Syndrome -- Pathophysiology -- Treatment of Complex Regional Pain Syndrome -- BoNT Treatment of CRPS -- Comment -- Residual Limb Pain and Phantom Pain -- Pharmacological Treatment -- BoNT Treatment of RLP and PLP -- Comment -- Chapter Conclusion -- References -- Chapter 5: Botulinum Toxin Treatment in Migraine and Other Headaches -- Migraine -- Introduction -- Treatment -- Therapeutic Use of Calcitonin Gene-Related Peptide (CGRP) Inhibitors -- Botulinum Neurotoxin for Preventive Treatment of Migraine -- Episodic Migraine (EM) -- Comment -- Chronic Migraine -- BoNT Injection Technique in Chronic Migraine -- Patient Report -- The Issue of Medication Overuse in Chronic Migraine -- Long-Term Response to BoNTs in Chronic Migraine and Safety Issues -- Imploding Versus Exploding Migraine -- BoNT Treatment in Pediatric Chronic Migraine -- Treatment of Chronic Migraine with Other Botulinum Toxins -- IncobotulinumtoxinA (Xeomin) -- The Mechanism of Action of OnabotulinumtoxinA (onaA) in Chronic Migraine -- Comparison of Botulinum Toxin Treatment and CGRP Treatment -- Comment -- Tension-Type Headache (TTH) -- Pathophysiology -- Treatment -- BoNT Treatment of Tension-Type Headache (TTH) -- Comment -- Chronic Daily Headaches (CDH) -- Trigeminal Autonomic Cephalalgias (TAC) -- Cluster Headaches -- Treatment -- BoNT Treatment of Cluster Headaches -- Posttraumatic Headaches (PTH) -- Botulinum Toxin Treatment of Posttraumatic Headaches -- Comment -- References -- Chapter 6: Botulinum Neurotoxins and Chronic Low Back Pain -- Introduction. Anatomy of Low Back Muscles -- Pathophysiology of Chronic Low Back Pain -- Medical Treatment of Chronic Low Back Pain -- Evidence for Efficacy of BoNTs in Chronic Low Back Pain -- Studies -- Case Report -- How Does the Administration of Botulinum Toxin Improve Low Back Pain? -- Comment -- References -- Chapter 7: Botulinum Toxin Treatment of Plantar Fasciitis (Plantar Fasciopathy) -- Introduction -- Anatomy of Plantar Fascia -- Pathophysiology of Plantar Fasciitis -- Treatment of Plantar Fasciitis -- BoNT Treatment of Plantar Fasciitis -- Case Report -- Comparator Studies -- How Does BoNT Injections Improve Pain in Plantar Fasciitis? -- Conclusion -- References -- Chapter 8: Botulinum Toxin Treatment of Myofascial Pain Syndrome and Fibromyalgia -- Introduction -- Anatomy and Pathophysiology of Myofascial Pain Syndrome (MFPS) -- Treatment -- BoNT Treatment of Myofascial Pain Syndrome (MPS) -- Double-Blind, Placebo-Controlled Studies -- Comparator Studies -- Case Reports -- Patient (8-1): Myofascial Pain Syndrome with Two Trigger Points in One Muscle -- Patient (8-2): Multiple Trigger Points in Multiple Muscles -- Comment on the Efficacy of BoNT Therapy in Myofascial Pain Syndrome -- The Mechanism of Action of BoNTs in Myofascial Pain Syndrome (MPS) -- Fibromyalgia -- Botulinum Toxin Treatment of Fibromyalgia -- Comment -- References -- Chapter 9: Botulinum Toxin Therapy for Pelvic and Urogenital Pain -- Introduction -- Anatomy of the Pelvic Floor -- Treatment of Chronic Pelvic Pain -- Botulinum Toxin Treatment of Chronic Pelvic Pain -- Rational -- Botulinum Neurotoxins Studies in Chronic Pelvic Pain (CPP) -- Comment -- Botulinum Toxin Treatment of Dyspareunia and Vaginismus -- Vulvodynia -- Comment -- Painful Bladder Disorders -- Botulinum Toxin Treatment of BPS/IC -- Injection Technique -- The Proposed Mechanisms of BoNT Action in Bladder Pain. Comment -- References -- Chapter 10: Botulinum Toxin Treatment of Chronic Facial Pain: Trigeminal Neuralgia and Temporo-Mandibular Disorders -- Trigeminal Neuralgia (TN) -- Treatment -- Pharmacologic Treatment -- Surgical Treatment -- Anatomy and Physiology of Trigeminal Sensory System -- Botulinum Toxin Treatment of Trigeminal Neuralgia -- Human Studies of BoNTs in Trigeminal Neuralgia -- Case Report -- Comment -- Temporomandibular Disorder (TMD) -- Treatment -- Botulinum Toxin Treatment of TMD -- Comment -- Case Report (10-2) -- References -- Chapter 11: Botulinum Neurotoxins for Relief of Pain Associated with Spasticity -- Introduction -- Pathophysiology of Spasticity and Spasticity Related Pain (SRP) -- Treatment of Spasticity -- Nonpharmacological Treatment of Spasticity -- Pharmacological Therapy -- Procedural Approaches and Surgical Interventions -- Botulinum Toxin Studies in Spasticity That Have Included Assessment of Pain -- Upper Limb Spasticity-Related Pain in Adults -- Comment -- Case 11-1 -- Lower Limb Spasticity-Related Pain of Adults -- Case 2 -- Comment -- Effects of BoNT Treatment on Pain of Children with Cerebral Palsy and Spasticity -- Comment -- The Mechanism of Action of BoNTs in Spasticity-Related Pain (SRP) -- Conclusion -- References -- Chapter 12: Treatment of Dystonic Pain with Botulinum Neurotoxins -- Introduction -- Cervical Dystonia -- Treatment -- Effects of BoNTs on Pain Associated with Cervical Dystonia -- Comparator Studies -- Same Toxin, Different Doses -- Different Toxins -- Comment -- Case 12.1 -- Botulinum Toxin Treatment of Painful Dystonia in Neurodegenerative Disorders -- Case 12-2 -- Case -12-3 -- Comment -- Post-traumatic Dystonia -- Case 12-4 -- Comment -- References -- Chapter 13: Botulinum Toxin Treatment of Piriformis Syndrome -- Introduction -- Anatomy -- Pathophysiology of the Piriformis Syndrome. Treatment of the Piriformis Syndrome (PS) -- Botulinum Toxin Treatment of Piriformis Syndrome -- Double-Blind, Placebo-Controlled Studies of BoNTs in Piriformis Syndrome -- Technical Points -- Comparator Studies -- The Mechanism of Botulinum Toxin Action in Piriformis Syndrome -- Conclusion -- References -- Chapter 14: Botulinum Toxin Therapy for Prevention of Postsurgical Pain -- Introduction -- Postmastectomy Breast Reconstruction -- Botulinum Toxin Treatment of Pain After Breast Reconstructive Surgery -- Comment -- Posthemorrhoidectomy Pain -- Treatment of Posthemorrhoidectomy Pain -- Botulinum Toxin Treatment of Posthemorrhoidectomy Pain -- Blinded, Placebo Controlled Studies -- Randomized, Controlled Study -- Prospective, Randomized Comparator Studies -- Comment -- Prevention and Reduction of Posthernia Repair Pain -- Reduction of Severe Pain After Adductor Release Surgery -- Conclusion -- References -- Chapter 15: Botulinum Toxins (BoNTs) for Treatment of Pain in Orthopedic Disorders -- Introduction -- Chronic Lateral Epicondylitis (CLE) -- Botulinum Neurotoxin Studies in CLE -- Placebo-Controlled Studies -- Comparator Studies -- Comment -- Introduction -- Botulinum Toxin Treatment -- Comparator Studies -- Comment -- Botulinum Neurotoxin Treatment after Total Knee Arthroplasty -- Knee Pain with Vastus Lateralis Imbalance -- Botulinum Toxin Treatment -- Comments on the Use of BoNT Injections for Pain After Knee Arthroplasty and Vastus Lateralis Imbalance (Patellofemoral Syndrome) -- References -- Chapter 16: Botulinum Toxin in Dentistry and Treatment of Chronic Orofacial Pain -- Introduction -- Chronic Orofacial Pain -- Musculoskeletal Orofacial Pain -- Temporomandibular Disorders (TMDs) -- Definition, Classification, and Epidemiology -- Management of Temporomandibular Disorders. Efficacy of BoNT in the Treatment of Temporomandibular Disorders with Pain. |
| Record Nr. | UNINA-9910574064703321 |
Jabbari Bahman
|
||
| Cham, Switzerland : , : Springer, , [2022] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Cannabinoids and pain / / Samer N. Narouze, editor
| Cannabinoids and pain / / Samer N. Narouze, editor |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (xix, 339 pages) : illustrations (black and white) |
| Disciplina | 615.7827 |
| Soggetto topico |
Cannabinoids - Therapeutic use
Pain - Chemotherapy Cànnabis Ús terapèutic |
| Soggetto genere / forma | Llibres electrònics |
| ISBN |
9783030691868
3-030-69186-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Part I: Introduction to Cannabis -- 1: History of Cannabis -- 2: Cannabis Regulations -- Introduction -- Federal Regulations -- State Cannabis Laws -- Research Expansion -- Conclusion -- 3: The Demand for Medical Cannabis Education -- 4: Pain Physicians and Medical Cannabis: Attitudes, Believes, Preparedness and Knowledge -- Introduction -- Development and Description of the Applied Questionnaire -- Statistical Analysis -- Results -- Discussion -- Summary -- Medical Cannabis Questionnaire -- 5: Cannabis Terminology -- Introduction -- General Aspects of the Cannabis Plant -- Differences Between C. sativa and C. indica -- Cannabis Versus Hemp -- The Endocannabinoid System (ECS) -- Key Terminology -- Cannabis Products and Accessories -- Conclusion -- Part II: Cannabinoids Pharmacology -- 6: The Endocannabinoid System -- Introduction -- Brief History of Cannabis and Hemp -- Components of the Endocannabinoid System (ECS) -- eCBs and Their Signal Transduction Pathways -- Complexity of the Endogenous Cannabinoid System -- CB1 and CB2 Receptor -- Other Receptors -- Transporters -- Enzymes -- Physiological Actions of ECS -- 7: Cannabinoid Receptor 1 (CB1) -- CB1 Receptors -- CB1 Receptor Physiology, Pathology, and Pharmacology -- CB1 Signaling -- CB1 Receptor Distribution -- Neocortex -- Hippocampus -- Hypothalamic -- Midbrain Periaqueductal Gray -- Brain Stem Rostral Ventromedial Medulla -- Tolerance -- CB1 Receptor Ligands -- References -- 8: Cannabinoid Receptor 2 (CB2) -- Cannabinoid 2 Receptor -- CB2 Receptor Physiology and Pharmacology -- CB2 Receptor Distribution -- CB2 Signaling -- CB2 Chronic Pain Models -- Tolerance -- CB2 Receptor Ligands.
9: Endocannabinoids: Anandamide and 2-Arachidonoylglycerol (2-AG) -- Introduction -- Biosynthesis and Breakdown Pathways -- Anandamide -- 2-AG -- Endocannabinoids' Mechanism of Action -- Anandamide -- 2-AG -- Plasticity of Endocannabinoid Signaling -- Endocannabinoids in Pain -- Peripheral Mechanisms -- Spinal Mechanisms -- Supraspinal Mechanisms -- Conclusion -- 10: Phytocannabinoids: Tetrahydrocannabinol (THC) -- Phytocannabinoids -- Introduction -- Δ9-Tetrahydrocannabinol (THC) -- Mechanism of Action of THC -- Applied Pharmacology and Pharmacokinetics -- Absorption -- Smoking -- Oral -- Oro-mucosal and Intranasal -- Rectal -- Transcutaneous -- Distribution -- Metabolism and Elimination -- Conclusion -- 11: Phytocannabinoids: Cannabidiol (CBD) -- Phytocannabinoids -- Cannabidiol and Its Various Clinical Effects -- Pharmacodynamics of Cannabidiol -- Applied Pharmacology and Pharmacokinetics -- Smoking -- Oral -- Transcutaneous -- Volume of Distribution -- Metabolism -- Elimination -- Safety Profile and Side Effects -- Cannabidiol Interaction with Tetrahydrocannabinol -- Conclusion -- 12: Other Phytocannabinoids -- Introduction -- Synthesis of Phytocannabinoids -- Cannabinoids and the Endocannabinoid System (ECS) -- Minor Cannabinoids -- Cannabinol (CBN) -- Cannabigerol (CBG) -- Cannabichromene (CBC) -- Tetrahydrocannabivarin (THCV) -- Conclusion -- 13: Cannabis Drug Interactions -- Introduction -- Routes of Administration -- Cannabinoid Drug Interactions -- Specific Drug Interactions -- Over-the-Counter (OTC) Analgesics -- Neuropathic Agents -- Opiates -- Antiepileptics -- Psychotropics -- Anticoagulants and Antiplatelets: "Blood Thinners" -- Warfarin -- Direct Oral Anticoagulants -- Clopidogrel -- Heparin/Fondaparinux -- References -- Part III: Pharmaceutical Cannabinoids. 14: Dronabinol (Marinol®) -- Introduction -- Mechanism of Action -- Pharmacokinetics -- Therapeutic Use -- Safety, Toxicity, and Adverse Effects -- 15: Nabilone (Cesamet) -- Introduction -- Clinical Trials -- Pharmacology and Pharmacokinetics -- Dosage and Administration -- Monitoring, Adverse Events, Drug Interactions, and Abuse Potential -- Adverse Effects -- Drug Interactions -- Abuse Potential -- 16: Cannabidiol (Epidiolex) -- Introduction -- Clinical Trials -- Pharmacology and Pharmacokinetics -- Dosage and Administration -- Monitoring, Adverse Events, and Drug Interactions -- Adverse Effects -- Abuse Potential -- 17: Nabiximols (Sativex®) -- Introduction -- Nabiximols Production -- Nabiximols Approval and Indications -- Nabiximols Contraindication -- Nabiximols Evidence -- Nabiximols for MS-Related Spasticity -- Nabiximols for MS-Related Neuropathic Pain -- Nabiximols for Cancer-Related Pain -- Nabiximols for Chronic Pain -- Nabiximols Tolerability -- Nabiximols Dosage and Administration -- Administration -- Dosing -- Storage, Stability, and Dosage Form -- Storage and Stability -- Dosage Form -- Summary -- Part IV: Medical Cannabis -- 18: Cannabis Strains to Chemovars -- Introduction -- Cannabis sativa L. -- Cannabis Cultivation and Trichomes -- Importance of Trichomes -- Cannabis Constituents -- Cannabinoids -- Terpenoids -- Other Cannabis Compounds -- Entourage Effect of Cannabis Constituents -- Cannabis Classification: Strains Versus Chemovars -- Strains -- Chemovar -- Practical Chemovar Selection for Clinicians -- Summary -- 19: The Model of a Medical Cannabis Clinic -- Introduction -- Description of a Medical Cannabis Clinic -- Referral and Screening -- Initial Visit -- Follow-Up and Monitoring -- Patient Education and Physician Communication. Protocols and Procedure Guidelines -- Continuing Medical Education -- Research Development -- Conclusion -- References -- 20: Barriers for the Prescription of Cannabinoid-Based Medicines -- Introduction -- Barriers for Cannabinoid Prescription -- Social Stigma for the Use of Cannabis -- Myths Versus Realities of Medical Cannabis Use -- Research Gaps and Limitations to Justify Medical Cannabis Use -- Lack of Knowledge Regarding Cannabis Regulatory Frameworks -- Limited Medical Cannabis Education -- Development of Medical Cannabis Education Programs with High Scientific Content -- Conclusion -- 21: Practical Recommendations for the Use of Medical Cannabis -- Introduction -- Cannabinoid-Based Medicines: What Is Currently Available? -- Prescription or Pharmaceutical Cannabinoids -- Natural Cannabis -- Inhalation -- Practical Recommendations [11, 12] -- Oral Administration -- Practical Recommendations [11, 12] -- Therapeutic Properties of Cannabinoids: THC Versus CBD -- Practical Recommendations for the Prescription of Cannabinoid-Based Medicines -- Clinical Evidence to Support Cannabinoid Use in Specific Medical Conditions -- Is the Patient a Candidate for Cannabinoid Therapy? A Systematic Approach -- Conclusion -- 22: Cannabinoid-Based Medicines: Dosing, Titration & -- Monitoring -- Introduction -- Methods of Administration -- Inhalation: Smoking and Vaporizing -- Oral -- Oromucosal -- Topical -- Dosing -- Concentration and Potency -- Cannabis Flower Dosing -- Cannabis Oil Dosing -- Achieving Optimal Therapeutic Dose and Cannabis Rotation -- Cannabis Chemovar Rotation and Reduction -- Monitoring -- Summary -- 23: Cannabinoid-Based Medicines: Patient Safety Considerations -- Introduction -- Practical Considerations for Cannabis Use -- Considerations -- Immunocompromised Patients. Calcineurin Inhibitors, Protein Disulfide Isomerase (PD1) Inhibitors, and Biologics -- Chronic Kidney Disease -- Older Adults and Patients with Concurrent Medical Conditions -- Polypharmacy and Drug Interactions [10] -- Precautions -- Concurrent Active Mood or Anxiety Disorder -- Patients with Risk Factors for Cardiovascular Disease (CVD) -- Tobacco Use -- E-Cigarette Use -- Severe Liver Dysfunction or Disease -- Medications Associated with Sedation or Cognitive Impairment -- Driving and Safety Sensitive Occupations -- Relative Contraindications -- Individuals Under the Age of 25 -- Cannabis Use Disorder (CUD) -- Substance Use Disorder (SUD) and Consideration for Harm Reduction -- Contraindications -- Cardiovascular Disease -- Respiratory Disease -- Psychosis and Bipolar Disorders -- Pregnancy and Breastfeeding -- Summary -- Part V: Cannabinoids and Pain -- 24: Cannabinoids and Pain: Mechanisms of Action -- Introduction -- Endocannabinoids' Mechanism of Action -- Anandamide (AEA) -- 2-Arachidonoylglycerol (2-AG) -- Endocannabinoids and Pain Modulation -- Peripheral Mechanisms -- Spinal Mechanisms -- Supraspinal Mechanisms -- Anandamide and 2-AG Synergistic Effect -- Endocannabinoid Receptors -- CB1 Receptors -- Central CB1 Receptors -- Peripheral CB1 Receptors -- Central CB2 Receptors -- Peripheral CB2 Receptors -- Other Putative Endocannabinoid Receptors: TRPV1 and GPR55 -- TRPV1 -- GPR55 -- Phytocannabinoids (THC and CBD) -- THC -- CBD -- Mechanisms of Action in Pain Modulation -- THC -- CBD -- References -- 25: Cannabinoids and Pain: Clinical Evidence -- Introduction -- Chronic Non-cancer Pain -- Chronic Neuropathic Pain -- Fibromyalgia -- Rheumatoid Arthritis -- Cancer Pain -- Acute Nociceptive Pain -- Summary -- 26: Cannabinoids and Cancer Pain -- Introduction -- Relevant Mechanisms of Cancer Pain. Current Understanding of Clinical Studies. |
| Record Nr. | UNINA-9910488702303321 |
| Cham, Switzerland : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Journal of therapeutic ultrasound
| Journal of therapeutic ultrasound |
| Pubbl/distr/stampa | London : , : BioMed Central, , [2013]- |
| Descrizione fisica | 1 online resource |
| Disciplina | 616.07543 |
| Soggetto topico |
Diagnostic ultrasonic imaging
Ultrasonics in medicine Ultrasonic Therapy Ultrasonography Ultrasons Ús terapèutic |
| Soggetto genere / forma |
Periodical
Fulltext Internet Resources. Periodicals. Revistes electròniques. |
| ISSN | 2050-5736 |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | JTU |
| Record Nr. | UNISA-996204504403316 |
| London : , : BioMed Central, , [2013]- | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. di Salerno | ||
| ||
Journal of therapeutic ultrasound
| Journal of therapeutic ultrasound |
| Pubbl/distr/stampa | London : , : BioMed Central, , [2013]- |
| Descrizione fisica | 1 online resource |
| Disciplina | 616.07543 |
| Soggetto topico |
Diagnostic ultrasonic imaging
Ultrasonics in medicine Ultrasonic Therapy Ultrasonography Ultrasons Ús terapèutic |
| Soggetto genere / forma |
Periodical
Fulltext Internet Resources. Periodicals. Revistes electròniques. |
| ISSN | 2050-5736 |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | JTU |
| Record Nr. | UNINA-9910141576803321 |
| London : , : BioMed Central, , [2013]- | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Medicinal cannabis and CBD in mental heathcare / / Kylie O'Brien, Philip Blair
| Medicinal cannabis and CBD in mental heathcare / / Kylie O'Brien, Philip Blair |
| Autore | O'Brien Kylie |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (xxi, 576 pages) |
| Disciplina | 615.7827 |
| Soggetto topico |
Cannabinoids - Therapeutic use
Mental illness - Treatment Cànnabis Ús terapèutic Malalties mentals |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-78559-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
1: Introduction -- Why This Book? -- The Structure of the Book -- Limitations -- Medicinal Cannabis as Part of a Holistic Therapeutic Approach -- Your Journey -- A Final Note from Dr. Blair -- References -- 2: Endocannabinoid System -- Introduction -- Purpose of the Endocannabinoid System -- Components of the Endocannabinoid System: Overview -- Endogenous Ligands: Endocannabinoids -- Endocannabinoids in Brief -- Synthesis of AEA and 2-AG -- Binding to Receptors (Extracellular and Intracellular) -- Transport Across the Plasma Membrane -- Intracellular Reservoirs Challenge Classic Understanding of Endocannabinoid On-Demand Synthesis -- Degradation of Endocannabinoids -- AEA Degradation -- 2-AG Degradation -- New Signaling Molecules Generated -- A Fine-Tuned Modulation System -- AEA and 2-AG in More Detail -- Anandamide (AEA) -- 2-Arachidonylglycerol (2-AG) -- Key Difference Between Endocannabinoids and Phytocannabinoids -- Endocannabinoid-Like Compounds: PEA, OEA, and Oleamide -- N-palmitoylethanolamide (PEA) and Oleoylethanolamide (OEA) -- Oleamide -- Cannabinoid Receptors -- Discovery of Cannabinoid Receptors -- Location of Cannabinoid Receptors -- Location of CB1 Receptors: Overview -- Neuroprotection -- CB1 Receptors in the CNS -- Glutamate and GABAergic Receptors -- CB1 Receptors Are More Abundant than Mu-Opioid Receptors -- CB1 Receptors and Cerebromicrovascular Endothelial Cells -- CB1 Receptors in Peripheral Nervous System and Periphery -- CB1 Receptors in the Peripheral Nervous System -- CB1 Receptors in the Gut -- CB1 Receptors in the Skin -- CB1 Receptors in the Liver -- Contrary Actions in the Periphery Compared with CNS: CB1 Receptors in Adipocytes -- Intracellular CB1 Receptors -- Different Isoforms of CB1 Receptors -- Functions of CB1 Receptors -- Functions of Mitochondrial CB1 Receptors.
CB2 Receptors -- CB2 Receptors and the Immune System -- CB2 Receptors in the Brain -- Unique Features of CB2 Receptors Compared with CB1 Receptors -- CB2 Receptors in Other Organs and Tissues -- CB2 Receptors in Skin -- Mechanisms of Action of the Endocannabinoid System (ECS) -- Classic Understanding of How the ECS Works in the Nervous System -- Complexity of the ECS: Multiple Signaling Pathway Involvement -- Biased Agonism -- Heteromers -- The ECS in Non-neural Cells -- ECS Signal Transmission Via Microvesicles -- Other Receptor Targets for Endocannabinoids -- TRPV1 Receptors -- Peroxisome Proliferator-Activated Receptors (PPARs) -- GPR55 Receptors -- The Endocannabinoid System in Neuroprotection -- Development and the Endocannabinoid System -- The ECS in Early Life -- The Adolescent Brain and the ECS -- Endocannabinoid System Dysfunction and Disease -- The Concepts of Endocannabinoid Tone and Endocannabinoid Deficiency -- Diseases in Which ECS Dysfunction Is Implicated -- Endocannabinoid System Dysfunction and Mental Health -- Omega 3 and 6 PUFAs in the Brain Health -- Diet and Importance of Omega 3 Fatty Acids for a Healthy ECS -- Studies Linking Omega 3 Deficiency and Mental Health Conditions -- Link Between ECS, Omega 3, and Omega 6 -- Why Are Omega 3 PUFAs Important for Functioning of the ECS? -- Why Are Dietary Sources of Long-Chain PUFAs Important? -- The Problem with the Western Diet -- Hemp Seeds Have a Very Good Ratio of Omega 6/Omega 3 PUFAs -- Conclusion -- References -- 3: The Endocannabinoid System, Stress, and Mental Health -- Introduction -- Key Brain Structures Involved in the Regulation of Stress -- Corticolimbic System -- Roles of the Components of the Corticolimbic System -- Hypothalamic-Pituitary-Adrenal (HPA) Axis -- Other Areas -- The Stress Response -- The Autonomic Stress Response. Sympathetic Nervous System Mechanisms of Action -- Parasympathetic Nervous System Neuroanatomical Connections -- Measurement of ANS Activity -- Neuroendocrine Stress Response -- The HPA Axis in Stress -- Measurement of Neuroendocrine Activity -- Sex Differences in the Stress Response System Along the HPA Axis -- When the Stress Response Becomes Pathological -- Stress and Inflammation -- How Does Stress Activate Inflammatory Changes? -- Endocannabinoid System and Stress Regulation -- Several Lines of Evidence that the ECS Is a Regulator of the Stress Response -- Bidirectional Relationship Between Stress and the ECS -- ECS and the Autonomic Nervous System Stress Response -- ECS, the Corticolimbic System, and the HPA Axis -- ECS and Regulation of the HPA Axis -- How Is the ECS Involved in Acute and Chronic Stress? -- Acute Stress -- Chronic Stress -- The Endocannabinoidome (Extended ECS) and Stress -- Genes, Stress, and the Endocannabinoid System -- Social Isolation -- Environmental Enrichment -- Early Life Stress and the Endocannabinoid System -- Early Life Stress, Corticolimbic System, and HPA Axis Development -- Stress Responsivity -- Findings from Animal Models -- Early Life Stress and Genetic Patterns in Humans -- Sex Differences in How Early Life Stress Affects the ECS -- The Gut and Stress -- The Gut Microbiome and Stress -- Microbiota Changes and Stress -- The Gut Regulates the HPA Axis -- Leaky Gut and Mental Health -- The Endocannabinoidome, the Gut, and Links to Mental Health -- Inflammation, the Gut, and the ECS -- Cannabis Exposure and Stress Responsivity -- Conclusion -- References -- 4: Overview of Medicinal Cannabis -- Introduction -- Definition of Medicinal Cannabis -- Taxonomy: What Is in a Name? -- Hemp -- Hemp Oil and Hemp Seed Oil -- Historical Use of Cannabis as Medicine -- Cannabis in China -- Cannabis in Other Ancient Cultures. Medicinal Cannabis in the Western World -- Regulations in the USA -- Active Constituents of Cannabis -- Where Are the Phytocannabinoids and Terpenes Found? -- Entourage Effect -- Cannabis Strains/Cultivars and Active Constituent Profiles -- Genes and Environmental Conditions -- A Word of Caution About Reductionism -- Phytocannabinoids: Overview -- Cannabidiol -- Therapeutic Actions of CBD -- What Conditions Can CBD Potentially Treat? -- Mechanisms of Action of CBD -- CBD Modulates Endocannabinoid Tone and Adenosine Tone -- CBD Modulates Multiple Signalling Systems -- Immunological and Anti-Inflammatory Effects -- Antioxidant Activity -- Anti-Bacterial Effect -- Cellular Benefits in the Central Nervous System -- Effects on Cardiovascular System -- Anti-Cancer Activity and Exosomes -- CBD Antagonism and Potentiation of THC -- Potentiation -- Antagonism -- Cannabidiolic Acid (CBDA) -- Tetrahydrocannabinol (THC) -- Therapeutic Actions of THC -- Mechanism of Action of THC -- Anti-Inflammatory Effects -- Anti-Ageing Effects -- THCA-A -- Other Phytocannabinoids -- Cannabichromene (CBC) -- Tetrahydrocannabivarin (THCV) -- Terpenes -- Actions of Terpenes -- Forms of Medicinal Cannabis -- Oils Are Not Oils -- A Gap in Our Knowledge: Lack of Studies in Whole Plant Extracts -- Superiority of Whole Spectrum CBD Over Pure CBD Isolate Demonstrated -- Dangers of Meta-Analyses -- Routes of Delivery and Pharmacokinetics -- Inhalation -- Oral Route -- Topical Route, Other Routes -- Bioavailability of CBD -- Bioavailability and Onset and Duration of Action of THC -- Safety -- Going Forward: The United Nations and the Single Convention -- Conclusion -- References -- 5: Anxiety -- Introduction -- Anxiety: Overview -- Types of Anxiety Disorder -- Associated Comorbidities -- Treatment of Anxiety -- Pathomechanisms Involved in Anxiety. Role of the Amygdala and Prefrontal Cortex in Anxiety -- Serotonin in Anxiety -- Noradrenergic System Involvement in Anxiety -- GABA Involvement in Anxiety -- Immune Dysfunction and Inflammation in Anxiety -- Inflammation and Anxiety -- Oxidative Stress -- Neurogenesis and the Hippocampus -- Adult Hippocampal Neurons and the Stress Response -- Neuritogenesis and Anxiety -- The Endocannabinoid System in Anxiety -- HPA Axis in Anxiety -- Endocannabinoids, Cannabinoid Receptors and Anxiety -- Enzymes of the ECS -- TRPV1 -- Scientific Evidence: CBD in the Treatment of Anxiety -- Mechanisms of Action of CBD in Anxiety -- CBD and the Serotonergic System -- CBD and the HPA -- CBD, Neurogenesis and Neuritogenesis -- CBD and Endocannabinoid Degradation -- CBD, Inflammation and Immune Function -- CBD, Sleep and Anxiety -- Animal Research: Efficacy of CBD in Anxiety -- Animal Models of Anxiety: Elevated Plus Maze -- Anxiety Studies in Rodents -- Animal Studies of Chronic CBD Administration -- Pure CBD Isolate and the Bell-Shaped Dose-Response Curve in Animal Studies -- Animal Study of Pure CBD Versus Whole Plant CBD -- Animal Research of CBDA in Anxiety -- Human Research: Efficacy of CBD in Anxiety -- Surveys -- Regional Cerebral Brain Flow Studies: Anxiety and CBD -- Observational Study: CBD and Anxiety -- Case Studies and Case Series -- Randomised Controlled Trials: CBD for Treatment of Anxiety -- Systematic Reviews: CBD and Anxiety Treatment -- Scientific Evidence: THC in the Treatment of Anxiety -- Preclinical Research: Effects of THC on Anxiety -- Anti-inflammatory Effects -- Human Research: Effects of Cannabis and THC on Anxiety -- Brain Imaging Studies -- Survey of Whole Plant Cannabis: Are Some Strains Better in Alleviating Anxiety? -- Observational Studies -- Randomised Controlled Trials -- Systematic Reviews. Does Adding CBD to THC Lower Its Anxiogenic Effect?. |
| Record Nr. | UNINA-9910508449403321 |
|
O'Brien Kylie
|
||
| Cham, Switzerland : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Opioid Use in Critical Care : A Practical Guide
| Opioid Use in Critical Care : A Practical Guide |
| Autore | Pascual Jose L |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing AG, , 2021 |
| Descrizione fisica | 1 online resource (291 pages) |
| Altri autori (Persone) | GaultonTimothy G |
| Soggetto topico |
Opiacis
Ús terapèutic |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-77399-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | Opioid Use in Critical Care |
| Record Nr. | UNINA-9910495187003321 |
|
Pascual Jose L
|
||
| Cham : , : Springer International Publishing AG, , 2021 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Pharmaceutical Nanobiotechnology for Targeted Therapy / / edited by Hamed Barabadi, Ebrahim Mostafavi, Muthupandian Saravanan
| Pharmaceutical Nanobiotechnology for Targeted Therapy / / edited by Hamed Barabadi, Ebrahim Mostafavi, Muthupandian Saravanan |
| Edizione | [1st ed. 2022.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2022 |
| Descrizione fisica | 1 online resource (641 pages) |
| Disciplina | 615.19 |
| Collana | Nanotechnology in the Life Sciences |
| Soggetto topico |
Biotechnology
Biology - Technique Molecular biology Nanotechnology Biological Techniques Molecular Biology Biotecnologia farmacèutica Ultraestructura (Biologia) Ús terapèutic |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-031-12658-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Preface -- Chapter. 1. Outer Membrane Vesicles (OMVs) as a Platform for Vaccination and Targeted Drug Delivery -- Chapter. 2. CRISPR/Cas9 Nano-Delivery Approaches for Targeted Gene Therapy -- Chapter. 3. Lipoplexes and Polyplexes for Targeted Gene Delivery -- Chapter. 4. Aptamer-Based Targeted Drug Delivery Systems -- Chapter. 5. Artificial Exosomes as Targeted Drug Delivery Systems -- Chapter. 6. Nanoarchaeosomes in drug delivery -- Chapter. 7. Bioengineered Metallic Nanomaterials for Nanoscale Drug Delivery Systems -- Chapter. 8. Nanobody-Based Delivery Systems for Diagnosis and Therapeutic Applications -- Chapter. 9. Phytosomes Used for Herbal Drug Delivery -- Chapter. 10. Porphysomes and porphyrin-based nanomaterials for drug delivery system -- Chapter. 11. Ethosomes for Dermal and Transdermal Drug Delivery Systems -- Chapter. 12. Liposomes and Niosomes for Targeted Drugs and Gene Delivery Systems -- Chapter. 13. Dendrimers as Targeted Systems for Selective Gene and Drug delivery -- Chapter. 14. Polymersomes for Targeted Drug and Gene Delivery Systems -- Chapter. 15. Quantum-Dot-Based Nanomaterials for Diagnostic and Therapeutic applications -- Chapter. 16. Carbon-based Nanomaterials for Targeted Drug and Gene Delivery Systems -- Chapter. 17. Hybrid Multifunctional Nanomaterials for Diagnostic and Therapeutic Applications -- Chapter. 18. Polymeric Micelles for Targeted Drug Delivery Systems -- Chapter. 19. Polymeric Nanoparticles for Targeted Drug and Gene Delivery Systems -- Chapter. 20. Magnetic Nanoparticles for Diagnostic and Therapeutic Applications. |
| Record Nr. | UNINA-9910619279003321 |
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2022 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Potential therapeutic applications of nano-antioxidants / / Sharda Sundaram Sanjay, Ashutosh Kumar Shukla
| Potential therapeutic applications of nano-antioxidants / / Sharda Sundaram Sanjay, Ashutosh Kumar Shukla |
| Autore | Sanjay Sharda Sundaram |
| Pubbl/distr/stampa | Singapore : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (118 pages) |
| Disciplina | 613.286 |
| Soggetto topico |
Antioxidants - Therapeutic use
Antioxidants - Health aspects Antioxidants Ús terapèutic |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 981-16-1143-2 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910494562503321 |
|
Sanjay Sharda Sundaram
|
||
| Singapore : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
